EYE Summary (August 2024): Incredibly Undervalued, page-316

Here it is. From the half yearly result presentation earlier this year. Given the strong performance in the most recent half though, which likely exceeded expectations (especially globally), I wonder if this could be achieved earlier (perhaps by the AGM in November, when they release an additional sales update?).

You also have to wonder as well if they perhaps have too much cash in the bank? For a high growth company valued at only $50m on the verge of profitability, $10m is quite a lot. Whilst it helps to have a good buffer, it would be nice to see them quickly announce new product lines (such as the next gen Molteno) and expanded indications (iTrack Advance for closed angle) soon after they breakeven, and put that cash to good use. Use the existing large cash balance, and cash flows from iTrack Advance, to grow this company into the leading ophthalmology company on the ASX (and eventually globally as well)